Asimov unveiled its AAV Edge Stable Producer system delivering clonal, HEK293-based, suspension producer cell lines to replace transient plasmid production and claim titers up to 6E15 vg/L pre‑purification. The platform aims to remove GMP plasmid supply risk and lower manufacturing costs for AAV gene therapies. Complementing that, Mytos launched an automated CDMO built on its iDEM automation to scale stem‑cell derived therapies with targets of up to 1,500 autologous or 25,000 allogeneic doses annually. Together these announcements signal an industry shift to automation and stable producer systems to reduce variability and cost for advanced therapy manufacturing. Clarification: stable AAV producer lines incorporate viral genes into producer genomes to remove the need for repeated GMP plasmid transfection and enable consistent, scalable production.